KR102500034B1 - A composition comprising an extract of Thymus quinquecostatus Celak for treating and preventing hangover - Google Patents
A composition comprising an extract of Thymus quinquecostatus Celak for treating and preventing hangover Download PDFInfo
- Publication number
- KR102500034B1 KR102500034B1 KR1020200079532A KR20200079532A KR102500034B1 KR 102500034 B1 KR102500034 B1 KR 102500034B1 KR 1020200079532 A KR1020200079532 A KR 1020200079532A KR 20200079532 A KR20200079532 A KR 20200079532A KR 102500034 B1 KR102500034 B1 KR 102500034B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- thyme
- present
- hangover
- composition
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 79
- 206010019133 Hangover Diseases 0.000 title claims abstract description 39
- 241000329467 Thymus quinquecostatus Species 0.000 title claims description 6
- 239000000203 mixture Substances 0.000 title abstract description 49
- 241000246358 Thymus Species 0.000 claims abstract description 60
- 235000007303 Thymus vulgaris Nutrition 0.000 claims abstract description 60
- 239000001585 thymus vulgaris Substances 0.000 claims abstract description 60
- 230000036541 health Effects 0.000 claims abstract description 23
- 235000013376 functional food Nutrition 0.000 claims abstract description 15
- 239000004480 active ingredient Substances 0.000 claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 238000003809 water extraction Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 4
- 241000218657 Picea Species 0.000 claims 3
- 230000000694 effects Effects 0.000 abstract description 42
- 238000002474 experimental method Methods 0.000 abstract description 30
- 102000007698 Alcohol dehydrogenase Human genes 0.000 abstract description 21
- 108010021809 Alcohol dehydrogenase Proteins 0.000 abstract description 21
- 235000013305 food Nutrition 0.000 abstract description 17
- 230000003908 liver function Effects 0.000 abstract description 15
- 238000005259 measurement Methods 0.000 abstract description 14
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 abstract description 9
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 abstract description 9
- 230000002265 prevention Effects 0.000 abstract description 8
- 230000006872 improvement Effects 0.000 abstract description 7
- 241001465754 Metazoa Species 0.000 abstract description 6
- 238000012404 In vitro experiment Methods 0.000 abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 108
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 50
- 235000019441 ethanol Nutrition 0.000 description 50
- 238000002360 preparation method Methods 0.000 description 21
- 235000013361 beverage Nutrition 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 13
- 238000009472 formulation Methods 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 238000002156 mixing Methods 0.000 description 10
- 239000000843 powder Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000010171 animal model Methods 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 235000013336 milk Nutrition 0.000 description 6
- 210000004080 milk Anatomy 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 235000013373 food additive Nutrition 0.000 description 5
- 239000002778 food additive Substances 0.000 description 5
- -1 for example Substances 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 235000012149 noodles Nutrition 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 235000015243 ice cream Nutrition 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 206010024264 Lethargy Diseases 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 235000013622 meat product Nutrition 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000207923 Lamiaceae Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 240000002853 Nelumbo nucifera Species 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 235000015155 buttermilk Nutrition 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 235000014171 carbonated beverage Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 108010033145 microsomal ethanol-oxidizing system Proteins 0.000 description 2
- 208000013465 muscle pain Diseases 0.000 description 2
- 229950006238 nadide Drugs 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000001508 potassium citrate Substances 0.000 description 2
- 229960002635 potassium citrate Drugs 0.000 description 2
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 2
- 235000011082 potassium citrates Nutrition 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000013555 soy sauce Nutrition 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 1
- 241001070946 Chrysolepis Species 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000055850 Diospyros virginiana Species 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010061291 Mineral deficiency Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 235000011449 Rosa Nutrition 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 241000246044 Sophora flavescens Species 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000015241 bacon Nutrition 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 description 1
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 description 1
- 235000007746 carvacrol Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 229940069647 citric acid 1000 mg Drugs 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000010610 frozen noodles Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000020251 goat milk Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 description 1
- 235000008960 ketchup Nutrition 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000020121 low-fat milk Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- PEFNSGRTCBGNAN-QNDFHXLGSA-N luteolin 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 PEFNSGRTCBGNAN-QNDFHXLGSA-N 0.000 description 1
- SUTSVCLKBLJSPQ-UHFFFAOYSA-N luteolin 7-glucoside Natural products OC1C(O)C(O)C(CO)OC1C1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 SUTSVCLKBLJSPQ-UHFFFAOYSA-N 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 239000004223 monosodium glutamate Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000014059 processed cheese Nutrition 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940074110 rosa roxburghii fruit extract Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Abstract
본 발명은 백리향 추출물을 유효성분으로 함유하는 간기능 개선 및 숙취의 예방 및 치료용 조성물 및 건강기능식품에 대한 것이다. 본 발명의 백리향 추출물을 대상으로 한, 알코올 탈수소효소 (Alcohol dehydrogenase, ADH) 활성도 측정실험, 알데히드 탈수소효소 (Aldehyde dehydrogenase, ALDH) 활성도 측정실험 등의 시험관내 실험 (실험예 1); 급성 알코올 동물 모델을 이용한 혈중 아세트알데하이드 (acetaldehyde) 농도 효능 평가 동물실험(실험예 2) 등을 통하여 본 발명의 시료들이 강력한 간기능개선 및 숙취의 치료 및 예방효과를 발휘함을 확인하여 숙취의 예방 및 치료를 위한 약학 조성물, 건강기능식품 및 건강보조식품에 유용하게 이용될 수 있다.The present invention relates to a composition and health functional food for improving liver function and preventing and treating hangovers containing thyme extract as an active ingredient. In vitro experiments such as alcohol dehydrogenase (ADH) activity measurement experiment and aldehyde dehydrogenase (ALDH) activity measurement experiment (Experimental Example 1) for the thyme extract of the present invention; Prevention of hangover by confirming that the samples of the present invention exhibit strong liver function improvement and hangover treatment and prevention effects through animal experiments (Experimental Example 2), etc. And it can be usefully used in pharmaceutical compositions for treatment, health functional food and health supplement food.
Description
본 발명은 백리향 추출물을 포함하는 숙취의 예방 또는 치료용 조성물에 관한 것이다.The present invention relates to a composition for preventing or treating hangover containing a thyme extract.
[문헌 1] Swift R et al., Alcohol Health Res World 1998;22:54-60[Document 1] Swift R et al., Alcohol Health Res World 1998;22:54-60
[문헌 2] 한국특허등록 제 10-0620093호[Document 2] Korea Patent Registration No. 10-0620093
[문헌 3] 한국특허등록 제 10-1723022호[Document 3] Korean Patent Registration No. 10-1723022
[문헌 4] 권 등, 한국응용약물학회지, 2005, 13,p. 107[Document 4] Kwon et al., Journal of the Korean Society of Applied Pharmacy, 2005, 13, p. 107
[문헌 5] 대한민국 공개특허 제 10-2012-0044807호[Document 5] Korean Patent Publication No. 10-2012-0044807
[문헌 6] 대한민국 등록특허 제10-0828708호[Document 6] Republic of Korea Patent Registration No. 10-0828708
[문헌 7] 대한민국 등록특허 제10-0620093호[Document 7] Republic of Korea Patent Registration No. 10-0620093
[문헌 8] 대한민국 등록특허 제 10-1334887호[Document 8] Republic of Korea Patent Registration No. 10-1334887
[문헌 9] 대한민국 등록특허 제 10-1723022호[Document 9] Korean Patent Registration No. 10-1723022
[문헌 10] 정보섭등, 도해향약대사전, 영림사, 1990년, p868-869[Document 10] Jeong Bo-subdeung, Dohae Hyangyakdaejeonjeon, Younglimsa, 1990, p868-869
[문헌 11] Blandino, A et al., Biotechnology letters, 1997;19:651-654[Document 11] Blandino, A et al., Biotechnology letters, 1997;19:651-654
[문헌 12] Bostian, K et al., Biochemical Journal, 1978;173:787-798[Document 12] Bostian, K et al., Biochemical Journal, 1978;173:787-798
[문헌 13] You, Y et al., J Korean Soc Food Sci Nutr, 2016;10:1508-1512[Document 13] You, Y et al., J Korean Soc Food Sci Nutr , 2016;10:1508-1512
본 발명은 숙취의 예방 또는 치료용 조성물에 관한 것으로서, 구체적으로는 백리향 추출물을 포함하는 숙취의 예방 또는 치료용 조성물에 관한 것이다.The present invention relates to a composition for preventing or treating hangover, and more particularly, to a composition for preventing or treating hangover containing a thyme extract.
알코올은 뇌의 중추신경에 작용하여 일시적으로 기분을 좋게 하고 괴로움을 잊을 수 있으며, 사교 수단 및 스트레스 해소를 위한 식품으로 활용되고 있다. 하지만 음주 후 나타나는 숙취는 신체적, 정신적 현상으로 그 대표적인 증상으로는 메스꺼움, 구토, 현기증, 갈증, 무기력함, 두통, 근육통 등이 있다(Swift R et al., Alcohol Health Res World 1998;22:54-60).Alcohol acts on the central nervous system of the brain to temporarily improve mood and forget suffering, and is used as a means of socializing and food for relieving stress. However, hangover after drinking is a physical and mental phenomenon, and its typical symptoms include nausea, vomiting, dizziness, thirst, lethargy, headache, and muscle pain (Swift R et al., Alcohol Health Res World 1998;22:54- 60).
정상적인 에틸알콜 대사과정은 체내로 유입된 에틸알콜이 위장 또는 소장에서 흡수되어 혈관 내로 들어가서 간장으로 옮겨지게 된다. 간세포에는 알콜 탈수소효소(ADH, alcohol dehydrogenase)가 있어 알콜을 아세트알데히드로 산화시키고, 상기 아세트알데히드는 간세포에 있는 아세트알데히드 탈수소효소(ALDH, acetaldehyde dehydrogenase)에 의해 아세트산으로 분해되어 전신의 근육이나 지방조직으로 옮겨져 최종적으로는 탄산가스와 물로 분해된다. 또한, 상기 아세트알데히드 탈수소효소에는 아세트알데히드가 저농도이더라도 산화를 개시하는 Ⅱ 형과 아세트알데히드가 고농도가 되지 않으면 작용을 하지 않는 I 형이 있으나, 동양인은 일반적으로 Ⅱ 형 아세트알데히드 효소가 결핍 또는 부족하기 때문에 아세트알데히드의 산화가 서양인에 비해 느린 편이다. 산화되지 못한 아세트알데히드 및/또는 에탄올은 정상적인 신진대사를 방해하여 다양한 숙취현상을 느끼게 한다.(한국특허등록 제 10-0620093호)In the normal process of ethyl alcohol metabolism, ethyl alcohol introduced into the body is absorbed from the stomach or small intestine, enters the bloodstream, and is transferred to the liver. There is alcohol dehydrogenase (ADH) in hepatocytes, which oxidizes alcohol to acetaldehyde, and the acetaldehyde is decomposed into acetic acid by acetaldehyde dehydrogenase (ALDH) in hepatocytes, resulting in muscle or adipose tissue of the whole body and is finally decomposed into carbon dioxide gas and water. In addition, the acetaldehyde dehydrogenase includes type II, which initiates oxidation even at low concentrations of acetaldehyde, and type I, which does not work unless acetaldehyde is high in concentration, but Asians generally lack or lack type II acetaldehyde enzymes. Because of this, the oxidation of acetaldehyde is slow compared to Westerners. Unoxidized acetaldehyde and/or ethanol interfere with normal metabolism, causing various hangover symptoms. (Korean Patent Registration No. 10-0620093)
음주 후 알코올은 3가지 경로를 통해 대사되는데, 에탄올의 농도가 낮을 때는 위장관 또는 간에 존재하는 알코올 탈수소효소 (Alcohol dehydrogenase)와 아세트알데히드 탈수소효소 (Acetaldehyde dehydrogenase)의 작용에 의해, 에탄올의 농도가 높을 때는 소포체에 존재하는 마이크로좀 에탄올 산화체계 (MEOS: Microsomal ethanol oxidizing system)에 의해 아세트알데히드와 아세트산으로 대사되며, 이후 퍼옥시좀 (peroxisome)에 존재하는 카탈라제 (catalase)의 작용 등을 거쳐 이산화탄소 (CO2)와 물 (H2O)로 최종 분해된다. 적당량의 알코올이 유입되면 상기 기술한 대사체계가 원활하게 작용하여 알코올 때문에 일어나는 제반 증상이 일어나지 않지만, 다량의 알코올 유입 시 대사체계의 균형이 파괴되어 생체 항상성을 유지하지 못하게 되어 단기적으로는 두통 또는 두중감, 집중력 감퇴, 속쓰림 및 소화불량 등이 초래되고 장기적으로는 간 기능 장애가 발생할 수 있다.(한국특허등록 제 10-1723022호).After drinking, alcohol is metabolized through three pathways. When the concentration of ethanol is low, alcohol dehydrogenase and acetaldehyde dehydrogenase present in the gastrointestinal tract or liver act. It is metabolized into acetaldehyde and acetic acid by the microsomal ethanol oxidizing system (MEOS) present in the endoplasmic reticulum, and then converted to carbon dioxide (CO 2 ) through the action of catalase present in the peroxisome. ) and finally decomposed into water (H 2 O). When an appropriate amount of alcohol is introduced, the above-described metabolic system works smoothly and all symptoms caused by alcohol do not occur. Persimmon, loss of concentration, heartburn and indigestion, etc. may be caused, and liver dysfunction may occur in the long term. (Korean Patent Registration No. 10-1723022).
섭취된 알코올의 대사과정에서 필수적으로 생기는 아세트알데히드는 급성 알코올 숙취의 가장 큰 원인, 즉 메스꺼움, 구토, 현기증, 갈증, 무기력증, 근육통 등을 유발하여 일반인의 업무능력 저하로 인한 사회경제적 손실을 유발하게 된다.Acetaldehyde, which is essentially generated in the metabolic process of ingested alcohol, causes the biggest cause of acute alcohol hangovers, namely nausea, vomiting, dizziness, thirst, lethargy, and muscle pain, and causes social and economic losses due to reduced work ability of the general public. do.
숙취는 술을 마신 후에 나타나는 두통, 설사, 식욕부진, 오심, 구토, 오한, 식은땀 등의 증상을 뜻하며, 객관적인 증상으로는 인식, 운동능력 저하, 혈액학적 변화 및 호르몬의 변화를 일컫는다. 숙취의 원인은 탈수, 알코올 및 알코올 대사물 (아세트알데히드, 포름알데히드, 아세톤 등)의 독성, 흡수 장애에 의한 영양소 결핍 (혈당, 비타민, 무기질 결핍) 등인 것으로 알려져 있다. 숙취 정도는 유전에 따른 개인의 편차, 환경상태 (영양 상태, 운동 상태, 탈수 정도, 건강 상태)에 따라 정도의 차이가 매우 심하다 (권 등, 한국응용약물학회지, 2005, 13,p. 107) Hangover refers to symptoms such as headache, diarrhea, anorexia, nausea, vomiting, chills, and cold sweat that appear after drinking alcohol. It is known that the cause of a hangover is dehydration, toxicity of alcohol and alcohol metabolites (acetaldehyde, formaldehyde, acetone, etc.), and nutrient deficiency (blood sugar, vitamin, and mineral deficiency) due to malabsorption. The degree of hangover varies greatly depending on individual variation according to heredity and environmental conditions (nutritional status, exercise status, dehydration level, health status) (Kwon et al., Journal of the Korean Society of Applied Pharmacy, 2005, 13, p. 107)
기존에 다양한 추출물을 이용한 숙취해소용 조성물이 개발된 바 있다. 예를 들면, 대한민국 공개특허 제 10-2012-0044807호는 클로렐라를 유효성분으로 포함하는 간기능 개선 또는 숙취해소용 조성물; 대한민국 등록특허 제10-0828708호는 글루타치온 함유 효모 추출물, 유화 아연, 자리(Rosa roxburghi) 추출물, 황기(Engelgarditia chrysolpsis HANCE) 추출물, 및 연자육(Nelumbo nucifera) 추출물을 포함하는 숙취의 예방 또는 치료용 조성물; 대한민국 등록특허 제10-0620093호는 자리(Rosa roxburghii) 열매 추출물, 황기(Engelharditia chrysolepis HANCE) 잎 추출물, 연자육(Nelumbo nucifera) 추출물, 또는 이들이 조합으로 구성된 그룹에서 선택된 추출물을 활성성분으로서 포함하는 숙취 방지 또는 치료용 조성물; 대한민국 등록특허 제 10-1334887호는 고삼 (Sophora flavescens) 추출물, 상기 추출물의 건조물, 및 상기 추출물의 농축물로 이루어진 군에서 선택된 1종 이상을 유효성분으로 함유하는 알코올성 숙취 예방 또는 숙취 해소용 약학 조성물; 대한민국 등록특허 제 10-1723022호는 개오동나무 추출물을 함유하는 숙취 예방 또는 해소용 조성물 등을 개시하고 있다.In the past, a composition for relieving hangover using various extracts has been developed. For example, Korean Patent Publication No. 10-2012-0044807 discloses a composition for improving liver function or relieving hangover, containing chlorella as an active ingredient; Korean Registered Patent No. 10-0828708 discloses a composition for preventing or treating hangovers, including glutathione-containing yeast extract, emulsified zinc, Rosa roxburghi extract, Engelgarditia chrysolpsis HANCE extract, and Nelumbo nucifera extract; Republic of Korea Patent Registration No. 10-0620093 is anti-hangover containing an extract selected from the group consisting of Rosa roxburghii fruit extract, Engelharditia chrysolepis HANCE leaf extract, Nelumbo nucifera extract, or a combination thereof as an active ingredient or a therapeutic composition; Republic of Korea Patent Registration No. 10-1334887 discloses a pharmaceutical composition for preventing or relieving hangover from alcohol containing at least one selected from the group consisting of an extract of Sophora flavescens, a dried product of the extract, and a concentrate of the extract as an active ingredient. ; Korean Patent Registration No. 10-1723022 discloses a composition for preventing or relieving a hangover containing an extract of Gaepaul tree.
상기와 같은 종래의 숙취해소용 조성물들보다 두통 또는 두중감, 위장관 불쾌감, 갈증, 발한, 무력감 등에 대해서는 보다 우수한 높은 체감 해소 효과를 나타내는 숙취해소용 조성물에 대한 지속적인 개발이 요구되어 왔다.There has been a demand for continuous development of a hangover relieving composition that exhibits a higher sensory relieving effect than conventional hangover relieving compositions such as headache or heaviness, gastrointestinal discomfort, thirst, sweating, lethargy, and the like.
그러나, 상기 문헌의 어디에도 백리향 추출물 단독 성분 추출물의 숙취에 대한 치료효과에 대하여 개시되거나 교시된 바가 없다. However, nowhere in the above document is there any disclosure or teaching about the therapeutic effect of the single component extract of thyme extract on hangover.
백리향 (Thymus quinquecostatus Celak.; 꿀풀과: Labiatae)의 전초는 한국 각지 고산지에 분포하며, 성분으로는 스쿠텔라린-헤테로시드(Scutellarein-heterosode), 루테올린(luteolin)-7-글루코시드(glucoside), 카바크롤(carvacrol), 우르산(ursolic acid) 등의 성분이 알려져 있으며, 기관지염, 신경염 등에 효능이 있는 것으로 알려져 있다 (정보섭등, 도해향약대사전, 영림사, 1990년, p868-869).Thyme ( Thymus quinquecostatus Celak.; Lamiaceae: Labiatae) is distributed in high mountains throughout Korea, and its components include Scutellarein-heterosode, luteolin-7-glucoside Ingredients such as , carvacrol, and ursolic acid are known, and are known to be effective for bronchitis and neuritis (Jeong Bo-seop, Dohae Hyangyak Dictionary, Younglimsa, 1990, p868-869).
이에 본 발명자들은 숙취에 효과적인 치료제를 개발하기 위한 연구의 일환으로 백리향추출물을 대상으로 한, 알코올 탈수소효소 (Alcohol dehydrogenase, ADH) 활성도 측정실험, 알데히드 탈수소효소 (Aldehyde dehydrogenase, ALDH) 활성도 측정실험 등의 시험관내 실험 (실험예 1); 급성 알코올 동물 모델을 이용한 혈중 아세트알데하이드 (acetaldehyde) 농도 효능 평가 동물실험(실험예 2) 등을 통하여 본 발명의 시료들이 강력한 간기능개선 및 숙취의 치료 및 예방효과를 발휘함을 확인하고 본 발명을 완성하였다. Therefore, as part of the research to develop an effective hangover cure, the present inventors conducted an alcohol dehydrogenase (ADH) activity measurement experiment and an aldehyde dehydrogenase (ALDH) activity measurement experiment targeting thyme extract. In vitro experiment (Experimental Example 1); Evaluation of blood acetaldehyde concentration efficacy using an acute alcohol animal model Through animal experiments (Experimental Example 2), etc., it was confirmed that the samples of the present invention exhibit strong liver function improvement and hangover treatment and prevention effects, and the present invention completed.
본 발명의 과제는 백리향 추출물을 유효성분으로 함유하는 간기능 개선 또는 숙취해소용 약학 조성물, 건강기능식품 및 건강보조식품을 제공하기 위한 것이다.An object of the present invention is to provide a pharmaceutical composition for improving liver function or relieving hangover, health functional food and health supplement containing thyme extract as an active ingredient.
상기 목적을 해결하기 위해 본 발명은 백리향 추출물을 유효성분으로 함유하는 간기능 개선 또는 숙취 해소용 약학 조성물을 제공한다.In order to solve the above object, the present invention provides a pharmaceutical composition for improving liver function or relieving hangover containing thyme extract as an active ingredient.
또한, 본 발명은 백리향 추출물을 유효성분으로 함유하는 간기능 개선 또는 숙취해소용 건강기능식품을 제공한다. In addition, the present invention provides a health functional food for improving liver function or relieving hangover containing thyme extract as an active ingredient.
본원에서 정의되는 백리향 추출물은 정제수를 포함한 물, 메탄올, 에탄올, 부탄올 등의 탄소수 1 내지 4의 저급알코올 또는 이들의 혼합용매로부터 선택된 용매, 바람직하게는 물 또는 물 및 에탄올 혼합용매, 보다 바람직하게는 물 또는 10~80% 에탄올에 가용한 추출물을 포함한다. The thyme extract defined herein is a solvent selected from water including purified water, lower alcohols having 1 to 4 carbon atoms such as methanol, ethanol, and butanol, or mixed solvents thereof, preferably water or a mixed solvent of water and ethanol, more preferably Contains extracts soluble in water or 10-80% ethanol.
본원에서 정의되는 백리향은 전초, 뿌리, 잎, 가지, 열매 등의 부위를 포함한다. Thyme, as defined herein, includes parts such as shoots, roots, leaves, branches, fruits, and the like.
이하, 본 발명을 더욱 상세히 설명한다. Hereinafter, the present invention will be described in more detail.
본 발명의 추출물은 하기와 같은 제조방법으로 수득될 수 있다. The extract of the present invention can be obtained by the following manufacturing method.
예를 들어, 이하, 본 발명을 상세히 설명한다.For example, the present invention will be described in detail below.
본 발명의 백리향 추출물은 하기와 같이 제조될 수 있다. 건조된 백리향을 세척 및 세절 후 정제수를 포함한 물, 메탄올, 에탄올, 부탄올 등의 탄소수 1 내지 4의 저급알코올 또는 이들의 혼합용매로부터 선택된 용매, 바람직하게는 물 또는 물 및 에탄올 혼합용매, 보다 바람직하게는 물 또는 10~80% 에탄올을 수회 섞은 다음에 30℃ 내지 150℃, 바람직하게는 70℃ 내지 120℃의 온도에서 30분내지 48시간, 바람직하게는 1시간 내지 12시간 동안 초음파 추출법, 열수 추출법, 상온 추출법 또는 환류추출법, 바람직하게는 열수 추출법을 약 1 내지 20회, 바람직하게는 2 내지 10회 반복 수행하여 얻은 추출액을 여과, 감압 농축, 및 건조하여 본 발명의 백리향 추출물을 얻을 수 있다.The thyme extract of the present invention can be prepared as follows. After washing and slicing the dried thyme, water including purified water, a lower alcohol having 1 to 4 carbon atoms such as methanol, ethanol, butanol, or a solvent selected from mixed solvents thereof, preferably water or a mixed solvent of water and ethanol, more preferably After mixing with water or 10-80% ethanol several times, ultrasonic extraction method or hot water extraction method at a temperature of 30 ℃ to 150 ℃, preferably 70 ℃ to 120 ℃ for 30 minutes to 48 hours, preferably 1 hour to 12 hours The thyme extract of the present invention can be obtained by filtering, concentrating under reduced pressure, and drying the extract obtained by repeating the room temperature extraction method or the reflux extraction method, preferably the hot water extraction method, about 1 to 20 times, preferably 2 to 10 times.
상기에서 수득된 백리향추출물을 대상으로 한, 알코올 탈수소효소 (Alcohol dehydrogenase, ADH) 활성도 측정실험, 알데히드 탈수소효소 (Aldehyde dehydrogenase, ALDH) 활성도 측정실험 등의 시험관내 실험 (실험예 1); 급성 알코올 동물 모델을 이용한 혈중 아세트알데하이드 (acetaldehyde) 농도 효능 평가 동물실험(실험예 2) 등을 통하여 본 발명의 시료들이 강력한 간기능개선 및 숙취의 치료 및 예방효과를 발휘함을 확인하여 간기능 개선 및 숙취의 예방 및 치료를 위한 약학 조성물, 건강기능식품 및 건강보조식품을 제공가능하다.In vitro experiments such as alcohol dehydrogenase (ADH) activity measurement experiment and aldehyde dehydrogenase (ALDH) activity measurement experiment for the thyme extract obtained above (Experimental Example 1); Efficacy evaluation of blood acetaldehyde concentration using an acute alcohol animal model Improvement of liver function by confirming that the samples of the present invention exhibit strong liver function improvement and hangover treatment and prevention effects through animal experiments (Experimental Example 2) And it is possible to provide a pharmaceutical composition, health functional food and health supplement food for the prevention and treatment of hangover.
따러서, 본 발명은 상기 제조방법으로 수득된 백리향 추출물을 유효성분으로 함유하는 간기능 개선 및 숙취의 예방 및 치료용 약학조성물, 건강기능식품 또는 건강보조식품을 제공한다. Accordingly, the present invention provides a pharmaceutical composition, health functional food or health supplement food for improving liver function and preventing and treating hangover, containing the thyme extract obtained by the above preparation method as an active ingredient.
또한, 백리향은 오랫동안 식용되거나 생약으로 사용되어 오던 약재로서 독성 및 부작용 등의 문제가 없다. In addition, thyme is a medicinal material that has been used as edible or herbal medicine for a long time, and has no problems such as toxicity and side effects.
본 발명의 약학 조성물은, 조성물 총 중량에 대하여 상기 추출물을 0.1 내지 50 중량 %로 포함한다. The pharmaceutical composition of the present invention includes 0.1 to 50% by weight of the extract based on the total weight of the composition.
본 발명의 추출물을 포함하는 약학조성물은, 약학적 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다.The pharmaceutical composition containing the extract of the present invention may further include suitable carriers, excipients and diluents commonly used in the preparation of pharmaceutical compositions.
본 발명의 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일 리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록 시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다.Carriers, excipients and diluents that may be included in the composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate. , cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
본 발명의 추출물의 약학적 투여 형태는 이들의 약학적 허용 가능한 염의 형태로도 사용될 수 있고, 또한 단독으로 또는 타 약학적 활성 화합물과 결합뿐만 아니라 적당한 집합으로 사용될 수 있다. The pharmaceutical dosage form of the extract of the present invention may be used in the form of a pharmaceutically acceptable salt thereof, and may also be used alone or in combination with other pharmacologically active compounds as well as in a suitable set.
본 발명의 추출물을 포함하는 조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽 및 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. Compositions containing the extract of the present invention are formulated in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups and aerosols, external preparations, suppositories and sterile injection solutions, respectively, according to conventional methods. and can be used.
상세하게는, 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제 및 캡슐제 등이 포함되며, 이러한 고형제제는 상기 화합물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트 (calcium carbonate), 수크로스 (sucrose), 락토오스 (lactose) 및 젤라틴 등을 섞어 조제될 수 있다. 또한, 단순한 부형제 이외에 마그네슘 스테아레이트 및 탈크 같은 윤활제들도 사용될 수 있다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제 및 시럽제 등이 해당되는데, 흔히 사용되는 단순 희석제인 물 및 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제 및 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제 및 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리 에틸렌 글리콜 및 올리브 오일과 같은 식물성 기름 및 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용 될 수 있다. 좌제의 기제로는 위텝솔 (witepsol), 마크로골, 트윈 (tween) 61, 카카오지, 라우린지 및 글리 세로젤라틴 등이 사용될 수 있다. Specifically, when formulated, it may be prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules and capsules, and the like, and these solid preparations contain at least one excipient, for example, starch, calcium carbonate, sucrose, etc. ), lactose and gelatin. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid preparations for oral use include suspensions, solutions for oral use, emulsions, and syrups. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, aromatics, and preservatives may be included. there is. Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried formulations, and suppositories. Vegetable oils such as propylene glycol, polyethylene glycol, and olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents. As a base for the suppository, witepsol, macrogol, tween 61, cacao butter, laurin paper, and glycerogelatin may be used.
본 발명의 추출물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나 바람직한 효과를 위해서, 본 발명의 추출물은 0.0001 ~ 100 mg/kg으로, 바람직하게는 0.00 1 ~ 100 mg/kg의 양을 일일 1회 내지 수회로 나누어 투여할 수 있다. 조성물에서 본 발명의 추출물은 전체 조성물 총 중량에 대하여 0.0001 ~ 50 중량%의 함량으로 배합될 수 있다.The preferred dosage of the extract of the present invention varies depending on the condition and body weight of the patient, the severity of the disease, the type of drug, the route and duration of administration, but can be appropriately selected by those skilled in the art. However, for the desired effect, the extract of the present invention may be administered in an amount of 0.0001 to 100 mg/kg, preferably in an amount of 0.00 1 to 100 mg/kg once or several times a day. In the composition, the extract of the present invention may be formulated in an amount of 0.0001 to 50% by weight based on the total weight of the composition.
본 발명의 약학 조성물은 쥐, 마우스, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 투여의 모든 방식 은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁내 경막 및 뇌혈관내 (intracere broventricular) 주사에 의해 투여될 수 있다. The pharmaceutical composition of the present invention can be administered to mammals such as rats, mice, livestock, and humans through various routes. All modes of administration can be envisaged, eg oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine intrathecal and intracerebroventricular injections.
또한, 본 발명은 백리향 추출물을 유효성분으로 함유하는 간기능 개선 또는 숙취의 예방 또는 개선용 건강기능 식품을 제공한다. In addition, the present invention provides a health functional food for improving liver function or preventing or improving hangover containing thyme extract as an active ingredient.
본원에서 정의되는 "건강기능식품"은 건강기능식품에 관한 법률 제6727호에 따른 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 및 가공한 식품을 의미하며, "기능성"이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건 용도에 유용한 효과를 얻을 목적으로 섭취하는 것을 의미한다."Health functional food" as defined herein refers to food manufactured and processed using raw materials or ingredients having useful functionalities for the human body in accordance with the Health Functional Food Act No. 6727, and "functional" means It refers to intake for the purpose of obtaining useful effects for health purposes, such as regulating nutrients with respect to structure and function or physiological action.
본 발명의 건강기능식품은, 조성물 총 중량에 대하여 상기 추출물을 0.01 내지 95%, 바람직하게는 1 내지 80% 중량백분율로 포함한다.The health functional food of the present invention contains the extract in a weight percentage of 0.01 to 95%, preferably 1 to 80%, based on the total weight of the composition.
또한, 질환의 예방 또는 개선을 위한 목적으로 산제, 과립제, 정제, 캡슐제, 환제, 현탁액, 에멀젼, 시럽 등의 약학 투여형태 또는 티백제, 침출차, 건강 음료 등의 형태인 건강기능식품으로 제조 및 가공이 가능하다.In addition, for the purpose of preventing or improving diseases, pharmaceutical dosage forms such as powders, granules, tablets, capsules, pills, suspensions, emulsions, syrups, etc., or health functional foods in the form of tea bags, leachated tea, health drinks, etc. are manufactured and processing is possible.
또한, 본 발명은 백리향 추출물을 유효성분으로 함유하는 간기능 개선 또는 숙취 해소용 건강보조식품을 제공한다. In addition, the present invention provides a health supplement for improving liver function or relieving hangover containing thyme extract as an active ingredient.
본 발명의 추출물은 목적 질환의 예방 및 치료를 위한 약제, 식품 및 음료 등에 다양하게 이용될 수 있다. 본 발명의 추출물을 첨가할 수 있는 식품으로는, 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제 및 건강보조 식품류 등이 있고, 분말, 과립, 정제 및 캡슐 또는 음료인 형태로 사용할 수 있다.The extract of the present invention can be used in various ways such as pharmaceuticals, foods and beverages for the prevention and treatment of target diseases. Foods to which the extract of the present invention can be added include, for example, various foods, beverages, gum, tea, vitamin complexes and health supplements, and can be used in the form of powders, granules, tablets and capsules or beverages. there is.
또한 상기 건강기능식품은 식품첨가물을 추가로 포함할 수 있으며, "식품첨가물"로서의 적합여부는 다른 규정이 없는 한 식품의약품안전처에 승인된 식품첨가물공전의 총칙 및 일반시험법 등에 따라 해당 품목에 관한 규격 및 기준에 의하여 판정한다.In addition, the health functional food may additionally contain food additives, and the suitability as a "food additive" is determined according to the general rules of the Food Additive Code and general test methods approved by the Ministry of Food and Drug Safety, unless otherwise specified. It is judged according to the relevant standards and standards.
또한, 본 발명은 백리향 추출물을 유효성분으로 함유하는 숙취의 예방 또는 개선용 식품 또는 식품첨가물을 제공한다.In addition, the present invention provides a food or food additive for preventing or improving hangover containing thyme extract as an active ingredient.
상기 "식품첨가물공전"에 수재된 품목으로 예를 들어, 케톤류, 글리신, 구연산칼륨, 니코틴산, 계피산 등의 화학적 합성품, 감색소, 감초추출물, 결정셀롤로오스, 구아검 등의 천연첨가물, L-글루타민산나트륨제제, 면류첨 가알칼리제, 보존료제제, 타르색소제제 등의 혼합 제제류들을 들 수 있다.Examples of items listed in the “Food Additives Codex” include chemical synthetic products such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamic acid, natural additives such as dark pigment, licorice extract, crystalline cellulose, and guar gum, L- Mixed preparations such as monosodium glutamate preparations, noodle-added alkali preparations, preservative preparations, and tar color preparations may be mentioned.
본 발명의 추출물이 포함된 기능성 식품으로는 빵, 떡류, 건과류, 캔디류, 초콜릿류, 츄잉껌, 쨈류와 같은 과자류 아이스크림류, 빙과류, 아이스크림 분말류와 같은 아이스크림 제품류 우유류, 저지방 우유류, 유당분해우유, 가공유류, 산양유, 발효유류, 버터유류, 농축유류, 유크림류, 버터유, 자연치즈, 가공치즈, 분유류, 유청류와 같은 유가공품류 식육가공품, 알가공품, 햄버거와 같은 식육제품류 어묵, 햄, 소세지, 베이컨 등의 어육가공품과 같은 어육제품류 라면류, 건면류, 생면류, 유탕면류, 호화건먼류, 개량숙면류, 냉동면류, 파스타류와 같은 면류 과실음료, 채소류음료, 탄산음료, 두유류, 요구르트 등의 유산균음료, 혼합음료와 같은 음료 간장, 된장, 고추장, 춘장, 청국장, 혼합장, 식초, 소스류, 토마토케첩, 카레, 드레싱과 같은 조미식품 마가린, 쇼트닝 및 피자를 들 수 있으나, 이에 제한되는 것은 아니다.Functional foods containing the extract of the present invention include bread, rice cakes, dried confections, candies, chocolates, chewing gum, confectionery products such as jams, ice creams, ice creams, ice cream products such as ice cream powders, milks, low-fat milks, and lactose-decomposed milks. , Processed milk, goat milk, fermented milk, buttermilk, concentrated milk, milk cream, buttermilk, natural cheese, processed cheese, milk powder, dairy products such as whey Processed meat products, processed egg products, meat products such as hamburgers Fish cake, ham Fish meat products such as fish meat products such as sausages and bacon Ramen, dried noodles, fresh noodles, fried noodles, deluxe dried noodles, improved deep-fried noodles, frozen noodles, pasta, etc. Fruit drinks, vegetable drinks, carbonated drinks, soy milk , beverages such as lactobacillus beverages such as yogurt, beverages such as mixed beverages, soy sauce, soybean paste, gochujang, chunjang, cheonggukjang, mixed soy sauce, vinegar, sauces, tomato ketchup, curry, seasoning foods such as dressings, margarine, shortening, and pizza. It is not limited.
본 발명의 상기 추출물은 목적 질환의 예방 및 치료를 목적으로 식품 또는 음료에 첨가될 수 있다. 이 때, 식품 또는 음료 중의 상기 추출물의 양은 일반적으로 본 발명의 건강식품 조성물은 전체 식품 중량의 0.01 내지 15 중량%로 가할 수 있으며, 건강 음료 조성물은 100 ㎖를 기준으로 0.02 내지 30 g, 바람직하게는 0. 3 내지 10 g의 비율로 가할 수 있다. The extract of the present invention may be added to food or beverage for the purpose of preventing or treating a target disease. At this time, the amount of the extract in the food or beverage is generally 0.01 to 15% by weight of the total food weight of the health food composition of the present invention, and the health drink composition is 0.02 to 30 g based on 100 ml, preferably may be added at a rate of 0.3 to 10 g.
본 발명의 건강 음료 조성물은 지시된 비율로 필수 성분으로서 상기 추출물을 함유하는 것 외에 액체성분에는 특별한 제한점은 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등의 디사카라이드, 예를 들어 말토스, 슈크로스 등의 폴리 사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 자일리톨, 소르비톨 및 에리트리톨 등의 당알코올이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상 기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖당 일반적으로 약 1 내지 20 g, 바람직하게는 약 5 내지 12 g이다.The health beverage composition of the present invention has no particular limitations on liquid components other than containing the extract as an essential component in the indicated ratio, and may contain various flavors or natural carbohydrates as additional components like conventional beverages. Examples of the aforementioned natural carbohydrates include monosaccharides, such as disaccharides such as glucose and fructose, such as polysaccharides such as maltose and sucrose, such as common sugars such as dextrins and cyclodextrins. , sugar alcohols such as xylitol, sorbitol and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (thaumatin, stevia extract (e.g. rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can advantageously be used. The proportion of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 추출물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 추출물은 천연 과일 쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 조성물 100 중량부 당 0 내지 약 20 중량 부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the extract of the present invention is various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and enhancers (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its It may contain salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonation agents used in carbonated beverages, and the like. In addition, the extract of the present invention may contain fruit flesh for the production of natural fruit juice, fruit juice beverages and vegetable beverages. These components may be used independently or in combination. The proportion of these additives is not critical, but is generally selected from the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.
본 발명의 백리향 추출물을 대상으로 한, 알코올 탈수소효소 (Alcohol dehydrogenase, ADH) 활성도 측정실험, 알데히드 탈수소효소 (Aldehyde dehydrogenase, ALDH) 활성도 측정실험 등의 시험관내 실험 (실험예 1); 급성 알코올 동물 모델을 이용한 혈중 아세트알데하이드 (acetaldehyde) 농도 효능 평가 동물실험(실험예 2) 등을 통하여 본 발명의 시료들이 강력한 간기능개선 및 숙취의 치료 및 예방효과를 발휘함을 확인하여 숙취의 예방 및 치료를 위한 약학 조성물, 건강기능식품 및 건강보조식품에 유용하게 이용될 수 있다.In vitro experiments such as alcohol dehydrogenase (ADH) activity measurement experiment and aldehyde dehydrogenase (ALDH) activity measurement experiment (Experimental Example 1) for the thyme extract of the present invention; Prevention of hangover by confirming that the samples of the present invention exhibit strong liver function improvement and hangover treatment and prevention effects through animal experiments (Experimental Example 2), etc. And it can be usefully used in pharmaceutical compositions for treatment, health functional food and health supplement food.
도 1은 백리향의 급성 알코올 동물 모델을 이용한 혈중 아세트알데하이드 (acetaldehyde) 농도 효능 평가실험 결과이다. 1 is a result of an efficacy evaluation test of acetaldehyde concentration in blood using an acute alcohol animal model of thyme.
이하, 본 발명을 하기 실시예 및 실험예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail by the following Examples and Experimental Examples.
단, 하기 실시예 및 실험예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예 및 실험예에 의해 한정되는 것은 아니다. However, the following Examples and Experimental Examples are only to illustrate the present invention, and the content of the present invention is not limited by the following Examples and Experimental Examples.
실시예 1. 백리향 추출물의 제조Example 1. Preparation of thyme extract
사단법인 서울 약령시협회에서 구매한 건조된 백리향 (Thymus quinquecostatus Celak) 전초 15 g에 1차 증류수 400 ml을 넣어 105℃에서 3시간 열수 추출한 뒤에, 적당히 식힌 뒤 진공 펌프를 연결하여 여과지 (1 ㎛, 150 mm filter paper)로 여과하였다. 여과된 추출물을 -80℃ 초저온 냉동고(908, Forma 900 series. Thermo scientific, USA)에 보관 후 동결건조기(FD8512, Ilshin, Seoul, Korea)를 통해 파우더 형태로 백리향 추출물 1.7g 를 만들어 -20℃에서 보관하였고 이를 하기 실험예에 사용하였다 (이하, “TQ”라 함).Add 400 ml of primary distilled water to 15 g of dried thyme ( Thymus quinquecostatus Celak) whole plant purchased from the Seoul Yaknyeongsi Association, extract hot water at 105 ° C for 3 hours, cool it appropriately, connect a vacuum pump, and filter paper (1 ㎛, 150 mm filter paper). After storing the filtered extract in a -80℃ cryogenic freezer (908, Forma 900 series. Thermo scientific, USA), 1.7 g of thyme extract in powder form was prepared through a freeze dryer (FD8512, Ilshin, Seoul, Korea) at -20℃. It was stored and used in the following experimental example (hereinafter referred to as “TQ”).
실험예 1. Experimental example 1. In vitroIn vitro 활성 실험 active experiment
상기 실시예의 시료들의 취 해소 및 간기능 개선에 미치는 영향을 알아보기 위하여 하기와 같이 실험을 수행하였다 Experiments were performed as follows to determine the effect of the samples of the above examples on the elimination and improvement of liver function.
1-1. 알코올 탈수소효소 (Alcohol dehydrogenase, ADH) 활성도 측정1-1. Measurement of alcohol dehydrogenase (ADH) activity
상기 실시예의 시료들의 알코올 탈수소효소 (Alcohol dehydrogenase, ADH) 활성도 에 미치는 영향을 알아보기 위하여 문헌에 기재된 방법을 이용하여 하기와 같이 실험을 수행하였다 (Blandino, A et al., Biotechnology letters, 1997;19:651-654)In order to examine the effect of the samples of the above examples on the activity of alcohol dehydrogenase (ADH), the following experiment was performed using the method described in the literature (Blandino, A et al., Biotechnology letters, 1997;19 :651-654)
1-1-1. 실험 준비.1-1-1. ready to experiment.
동결건조된 효소원 S9 rat liver homogenate (MOLTOXTM, cat. NO;11-01L.2)을 0.1% 소혈청 알부민 (bovine serum albumin, Sigma aldrich, cat NO;A9647) 용액 8 ml에 녹여 0.45 ㎛ syringe filter로 여과한 후에 사용하였다.The lyophilized enzyme source S9 rat liver homogenate (MOLTOX TM , cat. NO;11-01L.2) was dissolved in 8 ml of a 0.1% bovine serum albumin (Sigma aldrich, cat NO; A9647) solution, and a 0.45 μm syringe was used. It was used after filtering with a filter.
반응액 조성은 증류수 1.4 ml, 1.0 M tris-HCl buffer pH 8.8 (iNtRON, cat NO;IBS-BT080) 0.75 ml, 20 mM β-Nicotinamide adenine dinucleotide hydrate (NAD+,Sigma aldrich, cat NO;N7004) 0.3ml, 100%에탄올 0.3 ml, 실시예 추출물 0.1 ml (시료 농도는 50, 200, 400, 800, 1200 ㎍/ml) 을 혼합해준다.The composition of the reaction solution was distilled water 1.4 ml, 1.0 M tris-HCl buffer pH 8.8 (iNtRON, cat NO;IBS-BT080) 0.75 ml, 20 mM β-Nicotinamide adenine dinucleotide hydrate (NAD + ,Sigma aldrich, cat NO;N7004) 0.3 ml, 0.3 ml of 100% ethanol, and 0.1 ml of Example extracts (sample concentrations of 50, 200, 400, 800, and 1200 μg/ml) are mixed.
1-1-2.실험과정1-1-2. Experiment process
효소원을 제외한 반응액을 조성비율로 혼합한 뒤, 효소원 0.15 ml을 혼합해주었다. 상기 혼합물을 96 well plate에 넣어준 뒤에 30℃ 에서 5분간 반응 후에 340 nm 에서 기기(EPOCH microplate reader, BioTek, USA)로 흡광도를 측정하였다.After mixing the reaction solution except for the enzyme source in the composition ratio, 0.15 ml of the enzyme source was mixed. After the mixture was placed in a 96-well plate and reacted at 30° C. for 5 minutes, absorbance was measured at 340 nm with a device (EPOCH microplate reader, BioTek, USA).
최종적으로 활성도 계산법은 추출물을 첨가하지 않은 군을 대조군으로 하고 추출물의 활성도는 대조군에 대한 상대 활성(%)으로 측정하였다.Finally, in the activity calculation method, the group to which the extract was not added was used as a control group, and the activity of the extract was measured as a relative activity (%) for the control group.
1-1-3.실험결과1-1-3. Experiment results
상기 실험 결과, 백리향의 알코올 탈수소효소 (Alcohol dehydrogenase, ADH) 활성도 측정실험 결과, 50 ㎍/ml 농도에서 100.43±1.19 %, 200 ㎍/ml 농도에서 102.91±0.49 %, 400 ㎍/ml 농도에서 108.40±1.24 %, 800 ㎍/ml 농도에서 117.28±1.83 %, 1200 ㎍/ml 농도에서 128.06±1.36 %으로 농도 의존적으로 활성도가 증가함을 확인하였다. 또한 백리향 농도에 따라 유의한 차이가 나타남을 관찰하였고, 백리향 1200 ㎍/ml에서 대조군에 비해 ADH 활성도가 유의적으로 1.28배 증가하였다.(표 1 참조)As a result of the above experiment, as a result of the alcohol dehydrogenase (ADH) activity measurement experiment of thyme, 100.43 ± 1.19 % at 50 µg/ml concentration, 102.91 ± 0.49 % at 200 µg/ml concentration, and 108.40 ± 108.40 ± at 400 µg/ml concentration. It was confirmed that the activity increased in a concentration dependent manner, from 117.28±1.83% at 1.24% and 800 μg/ml concentrations to 128.06±1.36% at 1200 μg/ml concentrations. In addition, a significant difference was observed depending on the concentration of thyme, and at 1200 μg / ml of thyme, ADH activity significantly increased 1.28 times compared to the control group (see Table 1).
1-2. 알데히드 탈수소효소 (Aldehyde dehydrogenase, ALDH) 활성도 측정1-2. Aldehyde dehydrogenase (ALDH) activity measurement
상기 실시예의 시료들의 알데히드 탈수소효소 (Aldehyde dehydrogenase, ALDH) 활성도에 미치는 영향을 알아보기 위하여 문헌에 기재된 방법을 이용하여 하기와 같이 실험을 수행하였다 (Bostian, K et al., Biochemical Journal, 1978;173:787-798)In order to examine the effect of the samples of the above examples on the activity of aldehyde dehydrogenase (ALDH), an experiment was performed as follows using the method described in the literature (Bostian, K et al., Biochemical Journal, 1978; 173 :787-798)
1-2-1. 실험 준비.1-2-1. ready to experiment.
동결건조된 효소원 S9 rat liver homogenate (MOLTOXTM, cat. NO;11-01L.2)을 0.1% 소혈청 알부민 (bovine serum albumin, Sigma aldrich, cat NO;A9647) 용액 8 ml에 녹여 0.45 ㎛ syringe filter로 여과한 후에 사용하였다.The lyophilized enzyme source S9 rat liver homogenate (MOLTOX TM , cat. NO;11-01L.2) was dissolved in 8 ml of a 0.1% bovine serum albumin (Sigma aldrich, cat NO; A9647) solution, and a 0.45 μm syringe was used. It was used after filtering with a filter.
본 반응액 조성은 증류수 2.1 ml, 1.0 M tris-HCl buffer pH 8.0 (iNtRON, cat NO; IBS-BT019) 0.3 ml, 20 mM β-Nicotinamide adenine dinucleotide hydrate (NAD+,Sigma aldrich, cat. NO; N7004) 0.1ml, 1M acetaldehyde (Sigma aldrich, cat. NO; 402788) 0.1ml, 3M KCl (potassium chloride, Sigma aldrich, cat. NO;P9541) 0.1ml, 0.33M2-mercaptoethanol (Sigma aldrich, cat. NO; M3148) 0.1ml, 실시예 시료 추출물 0.1 ml (시료 농도는 50, 200, 400, 800, 1200 ㎍/ml)을 혼합해 주었다. The composition of this reaction solution was distilled water 2.1 ml, 1.0 M tris-HCl buffer pH 8.0 (iNtRON, cat NO; IBS-BT019) 0.3 ml, 20 mM β-Nicotinamide adenine dinucleotide hydrate (NAD + ,Sigma aldrich, cat. NO; N7004 ) 0.1ml, 1M acetaldehyde (Sigma aldrich, cat. NO; 402788) 0.1ml, 3M KCl (potassium chloride, Sigma aldrich, cat. NO; P9541) 0.1ml, 0.33M2-mercaptoethanol (Sigma aldrich, cat. NO; M3148 ) 0.1 ml, Example sample extract 0.1 ml (sample concentrations were 50, 200, 400, 800, 1200 ㎍ / ml) were mixed.
1-2-2. 실험방법1-2-2. Experiment method
효소원을 제외한 반응액을 조성비율로 혼합한 뒤에, 효소원 0.1 ml을 혼합해 주었다. 상기 혼합물을 96 well plate에 넣어준 뒤에 30℃ 에서 5분간 반응 후, 340 nm 에서 기기 (EPOCH microplate reader, BioTek, USA)로 흡광도를 측정하였다.After mixing the reaction solution except for the enzyme source in the composition ratio, 0.1 ml of the enzyme source was mixed. After the mixture was placed in a 96 well plate and reacted at 30° C. for 5 minutes, absorbance was measured at 340 nm with a device (EPOCH microplate reader, BioTek, USA).
최종적으로 활성도 계산법은 추출물을 첨가하지 않은 군을 대조군으로 하고 추출물의 활성도는 대조군에 대한 상대 활성(%)으로 측정하였다.Finally, in the activity calculation method, the group to which the extract was not added was used as a control group, and the activity of the extract was measured as a relative activity (%) for the control group.
1-2-3. 실험결과1-2-3. Experiment result
상기 실험 결과, 백리향의 알데히드 탈수소효소 (Aldehyde dehydrogenase, ALDH) 활성도 측정결과, 50 ㎍/ml 농도에서 99.63±7.54 %, 200 ㎍/ml 농도에서 100.49±6.30 %, 400 ㎍/ml 농도에서 105.94±6.62 %, 800 ㎍/ml 농도에서 116.37±7.91 %, 1200 ㎍/ml 농도에서 128.54±7.78 %으로 농도 의존적으로 활성도가 증가하였다. 또한 백리향 농도에 따라 유의한 차이가 나타남을 관찰하였고, 백리향 1200 ㎍/ml에서 대조군에 비해 ALDH 활성도가 유의적으로 1.29배 증가하였다 (표 2 참조As a result of the above experiment, the aldehyde dehydrogenase (ALDH) activity of thyme was measured, 99.63 ± 7.54% at 50 μg / ml concentration, 100.49 ± 6.30% at 200 μg / ml concentration, 105.94 ± 6.62 at 400 μg / ml concentration The activity increased in a concentration dependent manner, with %, 116.37±7.91% at 800 μg/ml concentration and 128.54±7.78% at 1200 μg/ml concentration. In addition, a significant difference was observed depending on the concentration of thyme, and at 1200 μg / ml of thyme, the ALDH activity was significantly increased by 1.29 times compared to the control group (see Table 2).
실험예 2. Experimental example 2. In vivoIn vivo 효능 평가 Efficacy evaluation
상기 실시예의 시료들의 숙취해소 및 간기능 개선효능을 확인하기 위하여, 급성 알코올 동물 모델을 이용한 혈중 아세트알데하이드 (acetaldehyde) 농도 효능 평가실험을 기존문헌에 기재된 방법을 응용하여 수행하였다 (You, Y et al., J Korean Soc Food Sci Nutr, 2016;10:1508-1512).In order to confirm the hangover relief and liver function improvement effects of the samples of the above examples, an experiment to evaluate the effect of acetaldehyde concentration in blood using an acute alcohol animal model was performed by applying the method described in the existing literature (You, Y et al ., J Korean Soc Food Sci Nutr , 2016;10:1508-1512).
2-1.실험준비2-1. Experiment preparation
본 연구는 실험 동물의 실험 윤리기준 (Institutional Animal Care and Use Committee, JSR-2020-02-004-001-A)에 따라 실험을 수행하였다. This study was conducted according to the ethical standards for experimental animals (Institutional Animal Care and Use Committee, JSR-2020-02-004-001-A).
실험동물은 생후 8주 된 250~300g Sprague-Dawley 흰쥐(수컷)를 ㈜DBL(음성군, 한국)에서 제공받아 1주일간의 적응기간을 거친 뒤에 플라스틱 케이지에 2마리씩 사육하였다. Experimental animals were 8-week-old 250-300 g Sprague-Dawley rats (male) provided by DBL (Eumseong-gun, Korea), and after a week-long adaptation period, they were raised in pairs in plastic cages.
사육장은 인공조명에 의하여 아침 7시부터 저녁 7시까지 12시간으로 조절하였으며, 실내온도는 18~23℃와 40~60%의 습도를 유지하고 정수된 식수와 사료를 자유롭게 먹게 하였다.The breeding farm was controlled for 12 hours from 7:00 am to 7:00 pm by artificial lighting, the indoor temperature was maintained at 18-23 ° C and the humidity was 40-60%, and purified drinking water and feed were freely consumed.
급성 알코올 동물 모델은 18시간 절식된 흰쥐에게 농도별 실시예 추출물 50, 200 mg/kg을 투여 30분 후에 30% 에탄올 3g/kg를 투여 후 시간대별로 경정맥에서 1 ml을 채혈하였다.In the acute alcohol animal model, 50 and 200 mg/kg of the example extracts were administered to rats fasted for 18 hours, and 3 g/kg of 30% ethanol was administered 30 minutes after administration, and then 1 ml of blood was collected from the jugular vein at each time point.
실험군은 (a)대조군, (b)에탄올 군, (c) 실시예 추출물 50 mg/kg 투여 후 에탄올 투여군 (실시예 50 + 에탄올 군), (d)실시예 추출물 200 mg/kg 투여 후 에탄올 투여군 (실시예 200 + 에탄올 군)으로 총 4군으로 나누었다.Experimental groups are (a) control group, (b) ethanol group, (c) ethanol administration group after administration of 50 mg/kg of the example extract (Example 50 + ethanol group), (d) ethanol administration group after administration of 200 mg/kg of the example extract (Example 200 + ethanol group) was divided into a total of 4 groups.
채혈 시간은 실시예 추출물 투여 전 (0 분), 에탄올 투여 후 30 분, 60 분, 90 분, 300 분으로 5번 채혈하였다. The blood collection time was five times: before administration of the example extract (0 min), 30 minutes, 60 minutes, 90 minutes, and 300 minutes after administration of ethanol.
2-2.실험과정 (혈중 아세트알데하이드 수치 측정)2-2. Experiment process (measurement of acetaldehyde level in blood)
동물 경정맥에서 채혈한 혈액을 4℃ 에서 2000 rpm 으로 30분간 원심분리기(Combi 514R,(주)한일과학)로 원심분리한 후에 혈장을 분리해 아세트알데하이드 분석 kit (megazyme, K-ACHYD) 를 이용해 혈액내 아세트알데하이드 농도를 측정했다. The blood collected from the jugular vein of the animal was centrifuged at 4℃ and 2000 rpm for 30 minutes in a centrifuge (Combi 514R, Hanil Science Co., Ltd.), and then the plasma was separated and blood was analyzed using an acetaldehyde analysis kit (megazyme, K-ACHYD). I measured my acetaldehyde concentration.
2-3.실험결과2-3.Experiment results
백리향의 혈중 아세트알데하이드 수치를 측정한 결과, 알코올 투여전 0분에서 대조군이 15.40±3.68 g/㎖ 에탄올 군이 12.93±3.75 g/㎖, 백리향 50 + 에탄올 군이 13.21±3.44 g/㎖, 백리향 200 + 에탄올 군이 13.47±3.33 g/㎖ 으로 군간 아세트알데하이드 수치는 차이가 없었다. 알코올 투여후 30분에서 대조군이 12.35±2.14 g/㎖, 에탄올 군이 21.51±4.15 g/㎖, 백리향 50 + 에탄올 군이 18.85±3.43 g/㎖, 백리향 200 + 에탄올 군이 19.90±4.62 g/㎖ 으로 에탄올 투여군들이 대조군에 비해 높은 아세트알데하이드 수치를 보였다. 알코올 투여후 60분에서 대조군이 16.00±3.83 g/㎖, 에탄올 군이 23.91±4.05 g/㎖, 백리향 50 + 에탄올 군이 19.08±2.60 g/㎖, 백리향 200 + 에탄올 군이 11.30±3.53 g/㎖ 으로 백리향 투여군들이 에탄올만 투여한 군에 비해 낮은 아세트알데하이드 수치를 보였다. 알코올 투여후 90분에서 대조군이 17.23±2.38 g/㎖, 에탄올 군이 17.95±3.78 g/㎖, 백리향 50 + 에탄올 군이 15.60±5.10 g/㎖, 백리향 200 + 에탄올 군이 8.43±1.64 g/㎖로 백리향 투여군들이 에탄올만 투여한 군에 비해 낮은 아세트알데하이드 수치를 보였다. 알코올 투여후 300분에서 대조군이 11.65±1.19 g/㎖, 에탄올 군이 18.11±1.58 g/㎖, 백리향 50 + 에탄올 군이 12.10±1.86 g/㎖, 백리향 200 + 에탄올 군이 14.77±2.39 g/㎖으로 백리향 투여군들이 에탄올만 투여한 군에 비해 낮은 아세트알데하이드 수치를 보였다.As a result of measuring the level of acetaldehyde in the blood of thyme, at 0 minutes before alcohol administration, the control group was 15.40±3.68 g/ml, the ethanol group was 12.93±3.75 g/ml, the thyme 50 + ethanol group was 13.21±3.44 g/ml, and the thyme 200 + Ethanol group was 13.47 ± 3.33 g / ㎖, there was no difference in acetaldehyde level between groups. At 30 minutes after alcohol administration, the control group was 12.35±2.14 g/ml, the ethanol group was 21.51±4.15 g/ml, the thyme 50 + ethanol group was 18.85±3.43 g/ml, and the thyme 200 + ethanol group was 19.90±4.62 g/ml. As a result, the ethanol-administered group showed higher acetaldehyde levels than the control group. At 60 minutes after alcohol administration, the control group was 16.00 ± 3.83 g / ml, the ethanol group was 23.91 ± 4.05 g / ml, the thyme 50 + ethanol group was 19.08 ± 2.60 g / ml, the thyme 200 + ethanol group was 11.30 ± 3.53 g / ml As a result, the thyme-treated group showed lower acetaldehyde levels than the ethanol-only group. At 90 minutes after alcohol administration, the control group was 17.23±2.38 g/ml, the ethanol group was 17.95±3.78 g/ml, the thyme 50 + ethanol group was 15.60±5.10 g/ml, and the thyme 200 + ethanol group was 8.43±1.64 g/ml. The thyme-treated group showed lower acetaldehyde levels than the ethanol-only group. At 300 minutes after alcohol administration, the control group was 11.65±1.19 g/ml, the ethanol group was 18.11±1.58 g/ml, the thyme 50 + ethanol group was 12.10±1.86 g/ml, and the thyme 200 + ethanol group was 14.77±2.39 g/ml. As a result, the thyme-treated group showed lower acetaldehyde levels than the ethanol-only group.
알코올 투여 후 90분에서 백리향 200 + 에탄올 군이 에탄올 군에 비해 현격하게 감소함을 관찰하였다. 또한 알코올 투여로 인해 혈중 아세트알데하이드 농도가 군간에 유의한 차이가 나타남을 관찰하였다. (표 3 참조) 백리향의 급성 알코올 동물 모델을 이용한 혈중 아세트알데하이드 (acetaldehyde) 농도 효능 평가실험에서 알코올 투여로 인해 혈중 아세트알데하이드 농도가 군간에 유의한 차이가 나타남을 확인하였고, 알코올 투여 90분에서 백리향 200 mg/kg 투여군이 에탄올군에 비해 아세트알데하이드 농도가 의미있게 감소하였다 (도 1). At 90 minutes after alcohol administration, it was observed that the thyme 200 + ethanol group significantly decreased compared to the ethanol group. In addition, it was observed that there was a significant difference between the groups in blood acetaldehyde concentration due to alcohol administration. (See Table 3) In the blood acetaldehyde concentration efficacy evaluation experiment using an acute alcohol animal model of thyme, it was confirmed that there was a significant difference in blood acetaldehyde concentration between groups due to alcohol administration, and thyme at 90 minutes of alcohol administration The concentration of acetaldehyde in the 200 mg/kg administration group was significantly decreased compared to the ethanol group (FIG. 1).
통계 분석statistical analysis
데이터는 평균(mean) ± SD으로 표기하고 통계 분석은 소프트웨어(SPSS Inc., Chicago, IL, USA)를 이용하여 수행하였다. *p<0.05, **p<0.001 을 통계상 유의성이 있는 것으로 간주하였다. Data were expressed as mean ± SD, and statistical analysis was performed using software (SPSS Inc., Chicago, IL, USA). * p <0.05, ** p <0.001 were considered statistically significant.
하기에 본 발명의 추출물을 포함하는 조성물의 제제예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Hereinafter, formulation examples of the composition containing the extract of the present invention will be described, but the present invention is not intended to limit them, but only to be specifically described.
제제예 1. 산제의 제조Formulation Example 1. Preparation of powder
추출물 (TQ) ------------------------------------------ 20 mgExtract (TQ) ------------------------------------------ 20 mg
유당 --------------------------------------------------- 100 mgLactose ------------------------------------------------- -- 100 mg
탈크 ---------------------------------------------------- 10 mgTalc ------------------------------------------------- --- 10mg
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조한다.A powder is prepared by mixing the above ingredients and filling them in an airtight bag.
제제예 2. 정제의 제조Formulation Example 2. Preparation of tablets
추출물 (TQ) ----------------------------------------- 10 mgExtract (TQ) ----------------------------- 10 mg
옥수수전분 -------------------------------------------- 100 mgCorn Starch -------------------------------------------- 100 mg
유당 -------------------------------------------------- 100 mgLactose ------------------------------------------------- - 100mg
스테아린산 마그네슘 ------------------------------------- 2 mgMagnesium Stearate ------------------------------------- 2 mg
상기의 성분들을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조한다.After mixing the above ingredients, tablets are prepared by tableting according to a conventional tablet manufacturing method.
제제예 3. 캅셀제의 제조 Formulation Example 3. Preparation of capsule formulation
추출물 (TQ) ------------------------------------------- 10 mgExtract (TQ) ------------------------------------------- 10 mg
결정성 셀룰로오스 --------------------------------------- 3 mgCrystalline Cellulose --------------------------------------- 3 mg
락토오스 --------------------------------------------- 14.8 mgLactose --------------------------------------------- 14.8 mg
마그네슘 스테아레이트 --------------------------------- 0.2 mgMagnesium stearate --------------------------------- 0.2 mg
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조한다.Capsules are prepared by mixing the above ingredients and filling them into gelatin capsules according to a conventional capsule preparation method.
제제예 4. 주사제의 제조Formulation Example 4. Preparation of injection
추출물 (TQ) ------------------------------------------ 10 mgExtract (TQ) ------------------------------------------ 10 mg
만니톨 ------------------------------------------------ 180 mgMannitol ------------------------------------------------ 180 mg
주사용 멸균 증류수 ----------------------------------- 2974 mgSterile distilled water for injection ----------------------------------- 2974 mg
Na2HPO4,12H2O ------------------------------------------- 26 mgNa 2 HPO 4 ,12H2O ------------------------------------------- 26 mg
통상의 주사제의 제조방법에 따라 1 앰플당(2 ㎖) 상기의 성분 함량으로 제조한다.It is prepared with the above component content per 1 ampoule (2 ml) according to the conventional method for preparing injections.
제제예 5. 액제의 제조Formulation Example 5. Preparation of liquid formulation
추출물 (TQ) ------------------------------------------- 20 mgExtract (TQ) ------------------------------------------- 20 mg
이성화당 ------------------------------------------------- 10 gIseonghwadang ------------------------------------------------ - 10 g
만니톨 ---------------------------------------------------- 5 gMannitol ------------------------------------------------- --- 5g
정제수 --------------------------------------------------- 적량Purified water ------------------------------------------------- -- Appropriate amount
통상의 액제의 제조방법에 따라 정제수에 각각의 성분을 가하여 용해시키고 레몬향을 적량 가한 다음 상기의 성분을 혼합한 다음 정제수를 가하여 전체를 정제수를 가하여 전체 100 ㎖으로 조절한 후 갈색병에 충진하여 멸균시켜 액제를 제조한다.According to the conventional liquid preparation method, each component is dissolved in purified water, lemon flavor is added in an appropriate amount, the above components are mixed, and then purified water is added to adjust the total volume to 100 ml, and then filled in a brown bottle. Sterilize to prepare a liquid formulation.
제제예 6. 건강 식품의 제조Formulation Example 6. Manufacture of health food
추출물 (TQ) ------------------------------------------- 1000 ㎎ Extract (TQ) ------------------------------------------- 1000 mg
비타민 혼합물 -------------------------------------------- 적량Vitamin Blend -------------------------------------------- Appropriate amount
비타민 A 아세테이트 ------------------------------------- 70 ㎍ Vitamin A Acetate ------------------------------------- 70 μg
비타민 E ----------------------------------------------- 1.0 ㎎Vitamin E ----------------------------------------------- 1.0 mg
비타민 B1 --------------------------------------------- 0.13 ㎎Vitamin B1 --------------------------------------------- 0.13 mg
비타민 B2 --------------------------------------------- 0.15 ㎎ Vitamin B2 --------------------------------------------- 0.15 mg
비타민 B6 ---------------------------------------------- 0.5 ㎎Vitamin B6 ---------------------------------------------- 0.5 mg
비타민 B12 --------------------------------------------- 0.2 ㎍Vitamin B12 --------------------------------------------- 0.2 μg
비타민 C ------------------------------------------------ 10 ㎎ Vitamin C ------------------------------------------------ 10 mg
비오틴 -------------------------------------------------- 10 ㎍Biotin ------------------------------------------------- - 10 μg
니코틴산아미드 ----------------------------------------- 1.7 ㎎ Nicotinamide ----------------------------------------- 1.7 mg
엽산 ---------------------------------------------------- 50 ㎍Folic acid ------------------------------------------------- --- 50 μg
판토텐산 칼슘 ------------------------------------------ 0.5 ㎎ Calcium Pantothenate ------------------------------------------ 0.5 mg
무기질 혼합물 -------------------------------------------- 적량Mineral mixture -------------------------------------------- Appropriate amount
황산제1철 --------------------------------------------- 1.75 ㎎ Ferrous sulfate --------------------------------------------- 1.75 mg
산화아연 ---------------------------------------------- 0.82 ㎎ Zinc Oxide ---------------------------------------------- 0.82 mg
탄산마그네슘 ------------------------------------------ 25.3 ㎎ Magnesium Carbonate ------------------------------ 25.3 mg
제1인산칼륨 --------------------------------------------- 15 ㎎ Potassium Phosphate Monobasic --------------------------------------------- 15 mg
제2인산칼슘 --------------------------------------------- 55 ㎎ Dibasic Calcium Phosphate --------------------------------------------- 55 mg
구연산칼륨 ---------------------------------------------- 90 ㎎ Potassium Citrate ---------------------------------------------- 90 mg
탄산칼슘 ----------------------------------------------- 100 ㎎ Calcium Carbonate ----------------------------------------------------------- 100 mg
염화마그네슘 ------------------------------------------ 24.8 ㎎ Magnesium Chloride ------------------------------------------ 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강식품 조성물 제조에 사용할 수 있다.Although the composition ratio of the above vitamin and mineral mixture was prepared by mixing ingredients suitable for relatively healthy food in a preferred embodiment, the mixing ratio may be arbitrarily modified. , Granules can be prepared and used in the preparation of health food compositions according to conventional methods.
제제예 7. 건강 음료의 제조Formulation Example 7. Manufacture of health drink
추출물 (TQ) ------------------------------------------ 1000㎎Extract (TQ) ------------------------------ 1000mg
구연산 ------------------------------------------------- 1000 ㎎ Citric acid ------------------------------------------------- 1000mg
올리고당 ------------------------------------------------- 100 goligosaccharide ------------------------------------------------- 100 grams
매실농축액 ------------------------------------------------- 2 gPlum concentrate ------------------------------------------------ - 2 g
타우린 ----------------------------------------------------- 1 gTaurine ------------------------------------------------- ----1 g
정제수를 가하여 ------------------------------------ 전체 900 ㎖Add purified water ------------------------ total 900 ml
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간 동안 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2ℓ 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용한다. After mixing the above components according to the usual health drink manufacturing method, stirring and heating at 85 ° C. for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2-liter container, sealed and sterilized, and then refrigerated according to the present invention. It is used in the manufacture of health beverage compositions.
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 수요계층, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.Although the composition ratio is a mixture of ingredients suitable for a relatively favorite beverage in a preferred embodiment, the mixing ratio may be arbitrarily modified according to regional and ethnic preferences such as the class of demand, the country of demand, and the purpose of use.
Claims (7)
The dried thyme (Thymus quinquecostatus Celak) outpost was washed and cut, mixed with water several times, and then subjected to hot water extraction 2 to 10 times at a temperature of 70 ° C to 120 ° C for 1 hour to 12 hours. The obtained extract was filtered and reduced pressure A health supplement for relieving hangovers containing, as an active ingredient, the water extract of thyme spruce obtained through a manufacturing method of concentrating and drying.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200079532A KR102500034B1 (en) | 2020-06-29 | 2020-06-29 | A composition comprising an extract of Thymus quinquecostatus Celak for treating and preventing hangover |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200079532A KR102500034B1 (en) | 2020-06-29 | 2020-06-29 | A composition comprising an extract of Thymus quinquecostatus Celak for treating and preventing hangover |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20220001315A KR20220001315A (en) | 2022-01-05 |
KR102500034B1 true KR102500034B1 (en) | 2023-02-14 |
Family
ID=79349082
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200079532A KR102500034B1 (en) | 2020-06-29 | 2020-06-29 | A composition comprising an extract of Thymus quinquecostatus Celak for treating and preventing hangover |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102500034B1 (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100913243B1 (en) * | 2007-10-29 | 2009-08-24 | 박오하 | A drink composition for eliminating hangover |
-
2020
- 2020-06-29 KR KR1020200079532A patent/KR102500034B1/en active IP Right Grant
Non-Patent Citations (3)
Title |
---|
El-Newary, SA., et al., ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE, Vol. 10(4), pp.361~371 (2017.04.06.)* |
Food and Chemical Toxicology 50 (2012) 4191-4198* |
Molecules 2016, 21, 64* |
Also Published As
Publication number | Publication date |
---|---|
KR20220001315A (en) | 2022-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101490786B1 (en) | Composition comprising water extracts from fomitella fraxinea (fr.) imaz. for treating or preventing obesity | |
KR20160144791A (en) | Composition for relieving menopausal symptom | |
US20180296615A1 (en) | Pharmaceutical composition or functional health food for preventing and treating metabolic diseases, containing water extract of pleurotus eryngii var. ferulae (pf.) as active ingredient | |
KR101093998B1 (en) | Functional composition for the prevention of hangover and improving liver function | |
KR102366919B1 (en) | Functional health food composition for inhibiting muscle reduction comprising a mixed extract of mulberry twig, Eucommia bark, Acanthopanax, and black bean | |
JPWO2004112817A1 (en) | Celery family-derived extract and method for producing the same | |
KR20180042936A (en) | a composition comprising the mycelium culture medium from Schizophyllum commune as an active ingredient for preventing or treating liver disease and alleviating hangover | |
KR102500034B1 (en) | A composition comprising an extract of Thymus quinquecostatus Celak for treating and preventing hangover | |
KR20110051543A (en) | Composition for preventing or treating obesity comprising blueberry fermentation extract | |
KR102239066B1 (en) | Composition for preventing, ameliorating or treating metabolic diseases comprising mixture of plant extract as effective component | |
KR20070097868A (en) | Composition comprising an allium cepa l. skin extract for preventing and treating diabetes mellitus | |
JP7296611B2 (en) | Nitric oxide production accelerator | |
KR101001159B1 (en) | Composition for preventing or improving the diabete containing eriobotrya japonica extract | |
KR20080079374A (en) | Composition comprising extract of crude drug mixture and the preparation method therof | |
KR20220001317A (en) | A composition comprising an extract of Phlomis umbrosa Turcz for treating and preventing hangover | |
KR20220001316A (en) | A composition comprising an extract of Zanthoxylum schinifolium Siebold & Zucc. for treating and preventing hangover | |
KR100690071B1 (en) | Functional composition for the prevention and improvement of hangover | |
KR20200130031A (en) | Methods for controlling blood sugar, promoting fat metabolism and manufacturing yogurt of diet function by yakon extract | |
KR102552842B1 (en) | Functional food composition containing the fermented natural extracts and the process for the preparation thereof | |
KR102025572B1 (en) | Composition for preventing, ameliorating or treating metabolic diseases comprising mixture of Diospyros lotus leaf and grape fruit stem extract as effective component | |
KR20180006612A (en) | Compositions for preventing or treating diabetes mellitus comprising extract of Aster koraiensis or fraction thereof | |
US11779626B2 (en) | Composition for enhancing immunity or preventing or treating neurodegenerative diseases by using goji berries, mulberries and jujubes | |
KR20130029283A (en) | Composition for constipation | |
KR102302047B1 (en) | Composition for hepatoprotective and ameliorating hangover | |
KR102281263B1 (en) | Enzyme treated catechin product containing increased gallic acid, epicatechin and epigallocatechin content and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E90F | Notification of reason for final refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |